BACHEM HOLDING AG – Trademark Portfolio
Entity Type: 03
BACHEM HOLDING AG holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 8 filings in this category. The portfolio also extends into Class 40 (Treatment & Processing) across 4 Nice Classification classes. Currently, 4 trademarks are registered and 1 is pending. Notable registered marks include BACHEM and CLINALFA. The owner is based in BUBENDORF.
HAUPTSTRASSE 144
BUBENDORF 4416 , CH
Showing of trademarks Trademarks
Trademark Classifications
BACHEM HOLDING AG's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does BACHEM HOLDING AG have?
BACHEM HOLDING AG has 10 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 pending, 2 abandoned, 2 cancelled.
What trademark classes does BACHEM HOLDING AG file in?
BACHEM HOLDING AG files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 40 (Treatment & Processing), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are BACHEM HOLDING AG's most well-known trademarks?
BACHEM HOLDING AG's registered trademark portfolio includes well-known marks such as BACHEM and CLINALFA. These are among 4 currently registered trademarks in the portfolio.
What is BACHEM HOLDING AG's trademark registration success rate?
BACHEM HOLDING AG has a 50% trademark registration rate, with 4 out of 8 resolved applications resulting in successful registration. Currently, 1 application is pending review.